AU2018296426B2 - Methods for treating tumors - Google Patents

Methods for treating tumors Download PDF

Info

Publication number
AU2018296426B2
AU2018296426B2 AU2018296426A AU2018296426A AU2018296426B2 AU 2018296426 B2 AU2018296426 B2 AU 2018296426B2 AU 2018296426 A AU2018296426 A AU 2018296426A AU 2018296426 A AU2018296426 A AU 2018296426A AU 2018296426 B2 AU2018296426 B2 AU 2018296426B2
Authority
AU
Australia
Prior art keywords
gdbn
cells
nanoparticles
tumor
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018296426A
Other languages
English (en)
Other versions
AU2018296426A1 (en
Inventor
Awatef Allouch
Eric Deutsch
Frédéric LAW
François LUX
Jean-Luc Perfettini
Olivier Tillement
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
NH Theraguix SA
Universite Claude Bernard Lyon 1
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
NH Theraguix SA
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM, NH Theraguix SA, Universite Claude Bernard Lyon 1 filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2018296426A1 publication Critical patent/AU2018296426A1/en
Application granted granted Critical
Publication of AU2018296426B2 publication Critical patent/AU2018296426B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2018296426A 2017-07-05 2018-07-04 Methods for treating tumors Ceased AU2018296426B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305869.4 2017-07-05
EP17305869.4A EP3424533A1 (en) 2017-07-05 2017-07-05 Methods for treating tumors
PCT/EP2018/068099 WO2019008040A1 (en) 2017-07-05 2018-07-04 METHODS OF TREATING TUMORS

Publications (2)

Publication Number Publication Date
AU2018296426A1 AU2018296426A1 (en) 2020-01-16
AU2018296426B2 true AU2018296426B2 (en) 2024-04-04

Family

ID=59363059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018296426A Ceased AU2018296426B2 (en) 2017-07-05 2018-07-04 Methods for treating tumors

Country Status (9)

Country Link
US (1) US20210128730A1 (enExample)
EP (2) EP3424533A1 (enExample)
JP (1) JP7386711B2 (enExample)
KR (1) KR102799910B1 (enExample)
CN (1) CN110913909A (enExample)
AU (1) AU2018296426B2 (enExample)
CA (1) CA3068355A1 (enExample)
TW (1) TWI796340B (enExample)
WO (1) WO2019008040A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2959502B1 (fr) 2010-04-30 2012-09-07 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques ; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie
CA3148734A1 (en) 2019-07-29 2021-02-04 Nh Theraguix High-z-element containing nanoparticles for use in the treatement of tumors
FR3099883A1 (fr) 2019-08-14 2021-02-19 Nh Theraguix Nanoparticules pour le traitement du cancer par rayonnement de radiofréquence
TWI833803B (zh) * 2019-09-12 2024-03-01 法商Ｎｈ蕾哈吉公司 含有高ｚ元素之奈米顆粒在製備用於治療腫瘤之藥物之用途
EP3795178A1 (en) 2019-09-19 2021-03-24 Nh Theraguix Methods for triggering m1 macrophage polarization
EP4096781A1 (en) 2020-01-28 2022-12-07 RefleXion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy
AU2021270780A1 (en) 2020-05-15 2022-11-24 Centre Georges-François Leclerc Methods for image-guided radiotherapy
CA3084780A1 (en) * 2020-06-24 2021-12-24 Rodney HERRING Use of low iron oxide iron-doped titanium dioxide nanoparticles in the treatment of tumors and other diseases
FR3116216B1 (fr) 2020-11-19 2023-10-27 Nh Theraguix Procédé de préparation de nanoparticules
FR3116197A1 (fr) * 2020-11-19 2022-05-20 Nh Theraguix Procédé de traitement de tumeurs par captation du cuivre et/ou du fer
CN120359049A (zh) 2022-07-13 2025-07-22 蒙彼利埃大学 纳米颗粒和放射性药物的联合疗法
WO2024058504A1 (ko) * 2022-09-16 2024-03-21 (주)한국원자력 엔지니어링 앱스코팔 효과를 갖는, 암의 예방 또는 치료용 조성물 및 이를 이용한 암의 예방 또는 치료방법
EP4605019A2 (en) 2022-10-18 2025-08-27 Nh Theraguix Methods for imaging using spcct
WO2024236048A1 (en) 2023-05-16 2024-11-21 Nh Theraguix Combination therapy for treating tumors with radiotherapy
FR3151755A1 (fr) 2023-07-31 2025-02-07 Nh Theraguix Procédé de quantification de la concentration d’un agent de contraste et dispositif associé

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135101A2 (fr) * 2010-04-30 2011-11-03 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509967A (ja) 2000-09-25 2004-04-02 ザ、プロクター、エンド、ギャンブル、カンパニー 医学及び治療法の適用に使用するための金属錯体
FR2867180B1 (fr) 2004-03-02 2006-06-16 Univ Claude Bernard Lyon Nanoparticules hybrides comprenant un coeur de ln203 porteuses de ligands biologiques et leur procede de preparation
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
GB0704932D0 (en) * 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
WO2013185032A1 (en) * 2012-06-07 2013-12-12 President And Fellows Of Harvard College Nanotherapeutics for drug targeting
DK2867368T3 (da) * 2012-07-06 2022-01-31 Roussy Inst Gustave Samtidig detektering af kannibalisme og senescens som prognostisk markør for cancer
UA116007C2 (uk) * 2013-01-25 2018-01-25 Нанобіотікс Композиції неорганічних наночастинок у комбінації з іонізуючим випромінюванням для лікування раку
KR101662755B1 (ko) * 2015-04-28 2016-10-05 한국생명공학연구원 Nox5의 발현 또는 활성을 억제하는 제제를 포함하는 암 치료용 조성물
US11096962B2 (en) * 2015-05-28 2021-08-24 Nanobiotix Nanoparticles for use as a therapeutic vaccine
US20160354333A1 (en) * 2015-06-03 2016-12-08 UND Life Sciences, LLC Compositions of polyunsaturated fatty acids and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135101A2 (fr) * 2010-04-30 2011-11-03 Nanoh Nanoparticules ultrafines a matrice polyorganosiloxane fonctionnalisee et incluant des complexes metalliques; leur procede d'obtention et leurs applications en imagerie medicale et/ou therapie

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAUPIN F; FLAENDER M; DELORME R; BROCHARD T; MAYOL JF; ARNAUD J ET AL.: "Gadolinium nanoparticles and contrast agent as radiation sensitizers", PHYS MED BIOL, vol. 60, no. 11, 2015, pages 4449 - 4464, *

Also Published As

Publication number Publication date
KR20200026290A (ko) 2020-03-10
CN110913909A (zh) 2020-03-24
TW201906636A (zh) 2019-02-16
EP3648793A1 (en) 2020-05-13
KR102799910B1 (ko) 2025-04-25
JP7386711B2 (ja) 2023-11-27
TWI796340B (zh) 2023-03-21
CA3068355A1 (en) 2019-01-10
WO2019008040A1 (en) 2019-01-10
AU2018296426A1 (en) 2020-01-16
US20210128730A1 (en) 2021-05-06
JP2020525467A (ja) 2020-08-27
EP3424533A1 (en) 2019-01-09

Similar Documents

Publication Publication Date Title
JP7386711B2 (ja) 腫瘍を治療するための方法
Teo et al. Lanthanides: applications in cancer diagnosis and therapy: miniperspective
Du et al. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy
Jung et al. Overcoming the limits of hypoxia in photodynamic therapy: a carbonic anhydrase IX-targeted approach
Zheng et al. Metal nanoparticles as novel agents for lung cancer diagnosis and therapy
Kim et al. Multifunctional trastuzumab–chlorin e6 conjugate for the treatment of HER2-positive human breast cancer
Chen et al. Synergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer
Zhang et al. Dual radiosensitization and anti-STAT3 anti-proliferative strategy based on delivery of gold nanoparticle-oligonucleotide nanoconstructs to head and neck cancer cells
Mandl et al. Combining Pr3+-doped nanoradiosensitizers and endogenous protoporphyrin IX for X-ray-mediated photodynamic therapy of glioblastoma cells
Liu et al. One‐dose bioorthogonal gadolinium nanoprobes for prolonged radiosensitization of tumor
Liu et al. PTGES3 proteolysis using the liposomal peptide-PROTAC approach
Xie et al. Aptamer as a molecular tethering agent induces PrPC aggregation and degradation to inhibit melanoma proliferation
Cao et al. Dual‐Targeted Nanovesicles Induced Cancer Stem‐Like Cell Differentiation to Sensitize Hepatocellular Carcinoma Radiotherapy
EP3996753A2 (en) Methods and agents for the detection and treatment of cancer
Tripathi et al. Biological Cargo: Exosomes and their Role in Cancer Progression and Metastasis
EP2877095A2 (en) Imaging and therapeutic methods for treating parathyroid tumors
NL2027653B1 (en) Targeting system with improved uptake
CN101313219B (zh) 一种诊断和治疗方法及其所使用的试剂
US20230218781A1 (en) Methods for triggering m1 macrophage polarization
Yang et al. Combination of porous Se@ SiO2 nanospheres and docetaxel exhibits anti-castration-resistant prostate cancer activity by downregulating ATG14-dependent autophagy
JP2006517032A (ja) ある種の癌治療の有効性を評価するための方法
JP2023529660A (ja) エクストラドメイン－ｂフィブロネクチン標的プローブを用いた診断及びモニタリング
Joshi et al. Exosome and Other Extracellular Vesicles for Cancer Management
Li et al. Near-infrared fluorescent labeled CGRRAGGSC peptides for optical imaging of IL-11Rα in athymic mice bearing tumor xenografts
US20170176445A1 (en) Method for determining the level of hypoxia in a tumor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired